Proportion of participants with hSBA vaccine seroresponse at Day 6 post-MenACYW-TT booster.
Proportion of participants with hSBA vaccine seroresponse at Day 6 post-MenACYW-TT booster in MenACYW-TT primed (Group 1) and MCV4-CRM primed (Group 2) participants (PPAS1). Errors bars indicate 95% confidence intervals. Group 1, MenACYW-TT primed: MenACYW-TT booster; Group 2, MCV4-CRM primed: MenACYW-TT booster. *For a participant with a pre-vaccination titer <1:8, the post-vaccination titer must be ≥1:16; for a participant with a pre-vaccination titer ≥1:8, the post-vaccination titer must be at least 4-fold greater than the pre-vaccination titerMost participants in both groups demonstrated hSBA seroprotection by Day 6 post booster (Serogroup A, 91.3% [95% CI 79.2, 97.6] and 95.6% [95% CI 84.9, 99.5]; Serogroup C, 100% [95% CI 92.3, 100] and 97.8% [95% CI 88.2, 99.9]; Serogroup W, 100% [95% CI 92.3, 100] and 100% [95% CI 92.1, 100]; and Serogroup Y, 97.8% [95% CI 88.5, 99.9] and 100.0% [95% CI 92.1, 100], in Group 1 and Group 2, respectively). The Day 6 GMTs were also comparable in Group 1 and Group 2 for serogroups A and Y, and were higher for serogroups C and W in Group 1 (Supplementary Table 